About UCSF Search UCSF UCSF Medical Center

Laura J. Esserman, MD, MBA

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
esserman_laura

Professor, Departments of Surgery and Radiology, and Affiliate Faculty, Institute for Health Policy Studies, UCSF
Director, Carol Franc Buck Breast Care Center; Co-Leader, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center

Phone: (415) 353-7111 (appts)
Box 1710, UCSF
San Francisco, CA 94143-1710

View on UCSF Profiles


Additional Websites


Education

Harvard University, A.B., 1977, History of Science
Stanford University, M.D., 1983, Surgery
Stanford University, School of Business, M.B.A., 1993, Health Policy


Professional Experience

  • 1985-1988
    Postdoctoral Fellow, Dept. of Medicine, Division of Oncology, Stanford University School of Medicine
  • 1988-1990/1983-1985
    Resident in General Surgery, Stanford University School of Medicine
  • 1990-1991
    Chief Resident in General Surgery, Stanford University School of Medicine
  • 1991-1993
    Consultant, Stanford University Hospital, Cost Benefit Issues in the ICU
  • 1992-1993
    Staff General Surgeon, Palo Alto VeteranOs Administration
  • 1991-1993
    Trauma Surgeon, Santa Clara Valley Medical Center
  • 06/92-8/93
    Clinical Assistant Professor of Surgery, Stanford University Department of Surgery
  • 09/93-present
    Co-Director, Carol Franc Buck Breast Care Center, UCSF/Mount Zion Cancer Center, San Francisco, CA
  • 09/93-5/04
    Assistant Professor of Surgery, UCSF/Mount Zion Medical Center
  • 06/96-present
    Affiliate Faculty, Institute for Health Policy Studies, University of California, San Francisco, CA
  • 07/96-present
    Co-Director, High-Risk Program for Breast and Ovarian Cancer, UCSF/Mount Zion Cancer Center, San Francisco, CA
  • 04/97-present
    Joint Appointment, Department of Radiology, University of California, San Francisco, CA
  • 06/97-present
    Executive Committee, Integrative Medicine Program, UCSF/Mount Zion Cancer Center, San Francisco, CA, Associate Professor, Surgery & Radiology
  • 07/97-present
    Director, UCSF Carol Franc Buck Breast Care Center, UCSF Helen Diller Family Comprehensive Cancer Center at Mt. Zion, San Francisco, CA
  • 06/98-present
    Clinical Program Leader, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center at Mt. Zion, San Francisco, CA
  • 6/04-present
    Professor of Surgery and Radiology, UCSF/Mount Zion Medical Center
  • 2008-present
    Associate Director (Translational Informatics), Helen Diller Family Comprehensive Cancer Center, UCSF/Mount Zion Cancer Center, San Francisco, CA

Honors & Awards

  • 1974 Harvard University-Sophomore Standing
  • 1974, 75, 77 John J. Fomon Research Fellowship (American Cancer Society)
  • 1975 Harvard University-Susan B. Anthony Potter Prize
  • 1977 Harvard University-Magna Cum Laude
  • 1992 Certification: Board Certified, American College of Surgeons
  • 1998-2008 Breast Cancer Research Foundation Award
  • 2003 Showcase for Biotechnology
  • 2003 Landmark Lecture Award Windber Research Institute
  • 2005 SPORE (Specialized Programs of Research Excellence) Outstanding Investigator of the Year
  • 2007 Best Poster – Breast Oncology Program
  • 2008 Best Poster – Breast Oncology Program

Selected Publications

  1. Wells CJ, O'Donoghue C, Ojeda-Fournier H, Retallack HE, Esserman LJ. Evolving Paradigm for Imaging, Diagnosis, and Management of DCIS. J Am Coll Radiol. 2013 Dec; 10(12):918-23.
    View on PubMed
  2. Alvarado MD, Conolly J, Park C, Sakata T, Mohan AJ, Harrison BL, Hayes M, Esserman LJ, Ozanne EM. Patient preferences regarding intraoperative versus external beam radiotherapy following breast-conserving surgery. Breast Cancer Res Treat. 2014 Jan; 143(1):135-40.
    View on PubMed
  3. Eklund M, Esserman LJ. Screening: Biology dictates the fate of young women with breast cancer. Nat Rev Clin Oncol. 2013 Dec; 10(12):673-5.
    View on PubMed
  4. Campbell MJ, Wolf D, Mukhtar RA, Tandon V, Yau C, Au A, Baehner F, Van't Veer L, Berry D, Esserman LJ. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context. PLoS One. 2013; 8(10):e79114.
    View on PubMed
  5. Omer ZB, Hwang ES, Esserman LJ, Howe R, Ozanne EM. Impact of ductal carcinoma in situ terminology on patient treatment preferences. JAMA Intern Med. 2013 Oct 28; 173(19):1830-1.
    View on PubMed
  6. Esserman LJ, Thompson IM, Reid B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA. 2013 Aug 28; 310(8):797-8.
    View on PubMed
  7. Peled AW, Irwin CS, Hwang ES, Ewing CA, Alvarado M, Esserman LJ. Total Skin-Sparing Mastectomy in BRCA Mutation Carriers. Ann Surg Oncol. 2014 Jan; 21(1):37-41.
    View on PubMed
  8. Elson SL, Hiatt RA, Anton-Culver H, Howell LP, Naeim A, Parker BA, Van't Veer LJ, Hogarth M, Pierce JP, Duwors RJ, Hajopoulos K, Esserman LJ. The Athena Breast Health Network: developing a rapid learning system in breast cancer prevention, screening, treatment, and care. Breast Cancer Res Treat. 2013 Jul; 140(2):417-25.
    View on PubMed
  9. Alvarado MD, Mohan AJ, Esserman LJ, Park CC, Harrison BL, Howe RJ, Thorsen C, Ozanne EM. Cost-effectiveness analysis of intraoperative radiation therapy for early-stage breast cancer. Ann Surg Oncol. 2013 Sep; 20(9):2873-80.
    View on PubMed
  10. Mukhtar RA, Yau C, Rosen M, Tandon VJ. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol. 2013 Nov; 20(12):3823-30.
    View on PubMed
  11. Flowers CI, O'Donoghue C, Moore D, Goss A, Kim D, Kim JH, Elias SG, Fridland J, Esserman LJ. Reducing false-positive biopsies: a pilot study to reduce benign biopsy rates for BI-RADS 4A/B assessments through testing risk stratification and new thresholds for intervention. Breast Cancer Res Treat. 2013 Jun; 139(3):769-77.
    View on PubMed
  12. O'Donoghue C, Esserman L. Recognising the benefits and harms of breast cancer screening: an opportunity to target improvement. Br J Cancer. 2013 Jun 11; 108(11):2200-1.
    View on PubMed
  13. DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013 Jun 1; 19(11):2817-23.
    View on PubMed
  14. Peled AW, Esserman LJ. Reply: The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy. Plast Reconstr Surg. 2013 Feb; 131(2):279e.
    View on PubMed
  15. Pass M, Volz S, Teng A, Esserman L, Belkora J. Physician behaviors surrounding the implementation of decision and communication AIDS in a breast cancer clinic: a qualitative analysis of staff intern perceptions. J Cancer Educ. 2012 Dec; 27(4):764-9.
    View on PubMed
  16. Esserman L, Ozanne E, van't Veer L. Will early detection for breast cancer ever work? Clin Chem. 2013 Jan; 59(1):190-3.
    View on PubMed
  17. Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol. 2012 Dec 20; 30(36):4584-6; author reply 4588-9.
    View on PubMed
  18. Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, Hantel A, Henry NL, Muss HB, Smith TJ, Vogel VG, Wolff AC, Somerfield MR, Davidson NE. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013 Mar 1; 31(7):961-5.
    View on PubMed
  19. Wulfkuhle JD, Berg D, Wolff C, Langer R, Tran K, Illi J, Espina V, Pierobon M, Deng J, DeMichele A, Walch A, Bronger H, Becker I, Waldhör C, Höfler H, Esserman L. Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin Cancer Res. 2012 Dec 1; 18(23):6426-35.
    View on PubMed
  20. Lips EH, Mukhtar RA, Yau C, de Ronde JJ, Livasy C, Carey LA, Loo CE, Vrancken-Peeters MJ, Sonke GS, Berry DA, Van't Veer LJ, Esserman LJ, Wesseling J, Rodenhuis S, Shelley Hwang E. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Res Treat. 2012 Nov; 136(1):35-43.
    View on PubMed

Go to UCSF Profiles, powered by CTSI